Your browser is no longer supported. Please, upgrade your browser.
AGN Allergan plc daily Stock Chart
Allergan plc
IndexS&P 500 P/E- EPS (ttm)-10.57 Insider Own0.20% Shs Outstand335.25M Perf Week-3.81%
Market Cap73.59B Forward P/E12.23 EPS next Y17.96 Insider Trans-9.74% Shs Float335.14M Perf Month-7.12%
Income-3688.70M PEG- EPS next Q3.96 Inst Own88.20% Short Float2.31% Perf Quarter-11.18%
Sales14.74B P/S4.99 EPS this Y63.30% Inst Trans-5.42% Short Ratio2.90 Perf Half Y9.77%
Book/sh209.66 P/B1.05 EPS next Y11.53% ROA8.90% Target Price274.59 Perf Year-4.34%
Cash/sh26.70 P/C8.22 EPS next 5Y12.38% ROE15.90% 52W Range184.50 - 261.27 Perf YTD4.53%
Dividend2.80 P/FCF- EPS past 5Y-28.70% ROI0.10% 52W High-15.98% Beta1.20
Dividend %1.28% Quick Ratio1.20 Sales past 5Y26.00% Gross Margin87.60% 52W Low18.98% ATR3.76
Employees16700 Current Ratio1.30 Sales Q/Q5.10% Oper. Margin-17.40% RSI (14)24.86 Volatility1.59% 1.56%
OptionableYes Debt/Eq0.45 EPS Q/Q- Profit Margin80.50% Rel Volume0.66 Prev Close219.13
ShortableYes LT Debt/Eq0.37 EarningsMay 09 BMO Payout2.40% Avg Volume2.67M Price219.52
Recom2.10 SMA20-6.77% SMA50-7.40% SMA200-3.55% Volume1,770,195 Change0.18%
May-10-17Reiterated RBC Capital Mkts Outperform $279 → $284
May-10-17Downgrade Goldman Buy → Neutral
Feb-09-17Reiterated Mizuho Buy $273 → $275
Dec-09-16Reiterated Credit Suisse Outperform $301 → $274
Nov-17-16Reiterated Mizuho Buy $293 → $273
Nov-03-16Reiterated RBC Capital Mkts Outperform $300 → $279
Nov-01-16Reiterated Mizuho Buy $299 → $293
Oct-31-16Resumed Barclays Equal Weight $250
Oct-11-16Reiterated Mizuho Buy $305 → $299
Aug-19-16Upgrade Mizuho Neutral → Buy $248 → $318
Aug-09-16Reiterated RBC Capital Mkts Outperform $307 → $300
Aug-09-16Reiterated Deutsche Bank Buy $282 → $278
Aug-05-16Reiterated Mizuho Neutral $232 → $246
Jul-27-16Reiterated Leerink Partners Outperform $272 → $294
Jul-25-16Initiated Credit Suisse Outperform $327
May-13-16Reiterated Mizuho Neutral $250 → $232
Apr-18-16Resumed Goldman Buy $275
Apr-18-16Initiated Guggenheim Neutral
Apr-18-16Downgrade Piper Jaffray Overweight → Neutral $311 → $238
Apr-07-16Resumed Morgan Stanley Overweight $300
May-22-17 08:27AM  3 Drug Stocks Billionaire Money Managers Dumped Big-Time in the First Quarter Motley Fool
May-19-17 01:33PM  Valeant Pharmaceuticals: IntriguedReally?
09:48AM  Valeant (VRX) Decides to Extend Stay on Xifaxan's ANDA Zacks
May-17-17 10:01AM  Allergan's Irritable Bowel Drug Viberzi Approved in Canada Zacks
09:59AM  Cardiome (CRME) Q1 Loss Wider Than Expected, Sales Miss Zacks
07:20AM  Valeant and Actavis agree to stay litigation relating to Valeant's top-selling drug Xifaxan MarketWatch
May-16-17 01:40PM  Is Editas Facing a New Reality in CRISPR Land? 24/7 Wall St.
12:30PM  Cramer: Carl Icahn Was Right to Sell Apple at $95
12:30PM  Carl Icahn Was Right to Sell Apple at $95
09:34AM  Biotech Movers: Akebia, Editas, Novavax
07:45AM  Allergan's Eyepowerment Campaign Releases Survey Revealing the Importance of Eye Language and the Crucial Role it Plays in Our Communications PR Newswire
07:00AM  VIBERZI Now Approved in Canada for patients with irritable bowel syndrome with diarrhea (IBS-D) PR Newswire
May-15-17 08:41PM  Several top fund managers trim Allergan stakes in first quarter Reuters
05:59PM  John Paulson Takes A Shine To Telecom The Wall Street Journal
03:12PM  ETFs with exposure to Allergan Plc : May 15, 2017 Capital Cube
09:28AM  13-F Reveals Tepper's Big Bet on Bank of America Investopedia
08:00AM  Allergan to Present at the Bernstein Strategic Decisions Conference PR Newswire
01:00AM  Still an Allergan Fan; Oil Vey!: Doug Kass' Views
May-14-17 11:26AM  Edited Transcript of AGN earnings conference call or presentation 9-May-17 12:30pm GMT Thomson Reuters StreetEvents
May-12-17 08:10PM  Earnings Are Still Calling the Tune: Cramer's 'Mad Money' Recap (Friday 5/12/17)
06:20PM  High-profile Snap stakeholders revealed in filings Reuters
06:03PM  13-F Alert: Starboard Dumps Macy's; Appaloosa and Baupost Lighten up on Allergan
05:19PM  Tepper's Appaloosa Trims Bets on Pharmaceuticals The Wall Street Journal
04:08PM  Court Battle May Be Responsible For Drugmaker's 40% Spike Investor's Business Daily
03:25PM  Top Picks For The Rest Of 2017, Courtesy Of UBS Benzinga
11:38AM  Allergan Plc :AGN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 Capital Cube
08:49AM  Pharma Stock Roundup: Mylan, Teva Q1 Earnings, Roche Drug Misses in Pivotal Study Zacks
May-11-17 04:07PM  Hologic Topples On 'Blip' In Breast Health, Body-Sculpting Unit Investor's Business Daily
10:36AM  Understanding Allergans Valuation after the 1Q17 Results Market Realist
09:59AM  Final Trades: Valeant, Allergan and more CNBC Videos
09:08AM  What Happened to Allergans International Segment in 1Q17? Market Realist
08:00AM  Today's Research Reports on Stocks to Watch: Allergan and Celgene Accesswire
07:37AM  Behind Allergans US General Medicines Segment in 1Q17 Market Realist
12:19AM  Asian stocks mostly higher in quiet trading; oil prices gain Associated Press
May-10-17 06:05PM  Behind Allergans US Specialized Therapeutics Segment in 1Q17 Market Realist
04:52PM  4 Pressing Questions We Want Answered When Teva Pharmaceutical Reports Tomorrow Morning Motley Fool
04:45PM  Hologic Smashes Fiscal Q2 Sales Views, Beats On Profit By 4 Cents Investor's Business Daily
04:24PM  Inside Allergans 1Q17 Results: Revenue Streams Market Realist
04:17PM  US STOCKS-Wall St mixed after Trump fires FBI head; Nasdaq hits record high Reuters
03:28PM  Allergan Starts 'Pivotal' 2017 With a Beat, Plus Jim Cramer's Take
03:02PM  Biotech And Pharma Industry And Stock News Investor's Business Daily
02:17PM  US STOCKS-Wall Street mixed after Trump fires FBI head Reuters
02:05PM  Allergan Looking Shaky After So-So Quarter Investopedia
01:00PM  US STOCKS-Tepid earnings, Comey sacking weigh on Wall St Reuters
11:59AM  Jim Cramer Discusses Disney, Yelp, Nvidia, Allergan, Abercrombie, Macy's and Kohl's
11:25AM  US STOCKS-Wall St weighed down by weak earnings, Comey sacking Reuters
11:03AM  Jim Cramer on Allergan: There Are So Many Sellers Off the Goldman Downgrade
11:01AM  Cramer: 5 Timeless Rules When a Stock Breaks Down
10:04AM  Allergan Stock Falls on Declining U.S. Medicine Revenue, Goldman Downgrade
08:52AM  Allergan Plc breached its 50 day moving average in a Bearish Manner : AGN-US : May 10, 2017 Capital Cube
08:41AM  Edited Transcript of AGN earnings conference call or presentation 9-May-17 12:30pm GMT Thomson Reuters StreetEvents
06:32AM  Allergan: Cramer's Top Takeaways
03:00AM  Allergan Announces Tender Offers by Certain Subsidiaries PR Newswire
03:00AM  Allergan Announces Proposed Public Offering of Senior Notes to Refinance Existing Debt PR Newswire
01:08AM  [$$] Thin Is In as Allergan Dodges Generics Bullet The Wall Street Journal
May-09-17 07:11PM  Cramer Remix: Where the money leaving retail stocks could... CNBC Videos
06:59PM  Cramer Remix: Where the money leaving retail stocks could be headed CNBC
05:42PM  Allergan Says It Continues to Look at Stepping-Stone Deals
04:11PM  Allergan Earnings Top Estimates On Aesthetic, Eye Care Products Investor's Business Daily
01:01PM  Allergan posts loss as it writes down Teva holdings Reuters
12:57PM  Allergan posts loss as it writes down Teva holdings Reuters
11:38AM  [$$] Thin Is In as Allergan Dodges Generics Bullet The Wall Street Journal
10:26AM  Allergan (AGN) Beats Q1 Earnings Estimates, Ups 2017 View Zacks
09:46AM  Ironwood (IRWD) Q1 Loss Wider than Expected, Sales Miss Zacks
09:04AM  Allergan tops Street 1Q forecasts, deal fuels guidance hike Associated Press
08:23AM  Allergan (AGN) Beats Q1 Earnings & Sales; Ups 2017 View Zacks
08:02AM  Early movers: VRX, AGN, W, ODP, PRTY, VZ, WFC, UAL, P & more CNBC
08:00AM  Medicines360 and Allergan Present Four-Year Multi-Center Pivotal Trial Data of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg at the 2017 ACOG Meeting PR Newswire
07:50AM  UPDATE: Allergan tops earnings estimates on strength of Botox, eye care products MarketWatch
07:00AM  Allergan Reports Solid Start to 2017 with 5% Increase in First Quarter GAAP Net Revenues to $3.6 Billion PR Newswire
06:43AM  Market Recon: Worryingly, the Indices Seem to Be Almost Resting at Lofty Levels
May-08-17 05:05PM  4 Stocks In Buy Range Ahead Of Earnings Reports: Investing Action Plan Investor's Business Daily
04:28PM  Allergan's Q1 Sales Expected To Slip As Jazz Pharma Outperforms Investor's Business Daily
04:00PM  M&A Talks May Take Center Stage in Allergan's 1Q Earnings Call
03:21PM  Allergan Must Show Mergers, Drug Pipeline Can Make Up For Lost Sales
01:05PM  Allergan: Analysts Ratings and Recommendations Market Realist
11:26AM  Analyzing Allergans 1Q17 Revenue Estimates Market Realist
11:26AM  Allergans 1Q17 Earnings: Analysts Estimates Market Realist
May-07-17 11:06AM  Earnings Preview: What To Expect From Allergan On Tuesday Forbes
May-05-17 08:00AM  Allergan Announces Second Quarter 2017 Cash Dividend of $0.70 Per Ordinary Share PR Newswire
May-04-17 05:05PM  Here's Why Paratek Pharmaceuticals Rose as Much as 16.1% Today Motley Fool
10:34AM  What's in the Cards for Allergan (AGN) this Earnings Season? Zacks
08:00AM  Allergan to Present at the Bank of America Merrill Lynch Healthcare Conference PR Newswire
07:30AM  Allergan to Present New Data at the 2017 American College of Obstetricians and Gynecologists (ACOG) Clinical and Scientific Meeting in San Diego PR Newswire
May-02-17 07:30AM  Allergan Solidifies Strong Footprint at ARVO 2017 with Several Data Presentations PR Newswire
May-01-17 04:45PM  Allergan Plc Value Analysis (NYSE:AGN) : May 1, 2017 Capital Cube
02:43PM  Allergan Is Ready to Turn Higher
12:37PM  MKM: Health care could buck the 'sell in May' trend CNBC Videos
07:30AM  Allergan to Present New and Updated Linzess®, Viberzi®, Relamorelin, Linaclotide Delayed Release, and Cenicriviroc Data at Digestive Disease Week® 2017 PR Newswire
Apr-28-17 08:30AM  Allergan Successfully Completes ZELTIQ® Aesthetics Acquisition PR Newswire
08:22AM  Allergan Plc breached its 50 day moving average in a Bullish Manner : AGN-US : April 28, 2017 Capital Cube
Apr-26-17 01:12PM  Teva Confirms CFO Is Leaving
Apr-25-17 05:58PM  PBF Energy Set to Join S&P MidCap 400; Apollo Commercial Real Estate Finance and Waddell & Reed Financial to Join S&P SmallCap 600 PR Newswire
04:47PM  Jerome Dodson Keeps Buying McKesson, Axalta, Pentair
01:39PM  Gilead Sciences: NASH BridgesTo What?
07:31AM  Allergan Granted Marketing Authorization by the FDA for TrueTear, the First Intranasal Neurostimulating Device Proven to Temporarily Increase Tear Production PR Newswire
Apr-24-17 01:52PM  NASH: The next untapped pharma market gives investors many options Reuters
01:10PM  Trump Executive Order Could Revive Allergan-Pfizer Merger
09:42AM  3 Healthcare Bargain Stocks You Can Buy Right Now Motley Fool
07:38AM  Novartiss 1Q17 Estimates for Sandoz Market Realist
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Basgoz NesliDirectorMay 18Option Exercise84.441,889159,5077,919May 22 04:26 PM
Basgoz NesliDirectorMay 18Sale220.451,889416,4306,030May 22 04:26 PM
GALLAGHER MICHAEL RDirectorMay 04Option Exercise245.2517,6934,339,20820,272May 05 06:34 PM
BISARO PAULDirectorMar 02Sale246.6870,00017,267,561235,900Mar 06 06:59 AM
Meury WilliamChief Commercial OfficerDec 08Option Exercise109.1211,8071,288,38048,866Feb 14 09:13 PM
Basgoz NesliDirectorDec 08Sale188.7250094,3605,515Dec 09 05:56 PM
SAUNDERS BRENT LCEO and PresidentNov 21Buy189.135,250992,941106,564Nov 21 04:03 PM
Hilado Maria TeresaChief Financial OfficerNov 11Buy210.641,422299,53613,379Nov 15 05:18 PM